These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32727767)

  • 1. Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy.
    Kurokawa T; Hamai Y; Emi M; Ibuki Y; Yoshikawa T; Ohsawa M; Hirohata R; Okada M
    Anticancer Res; 2020 Aug; 40(8):4387-4394. PubMed ID: 32727767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Recurrence and Cancer Death After Trimodal Therapy for Esophageal Squamous Cell Carcinoma.
    Hamai Y; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Furukawa T; Kurokawa T; Ohsawa M; Okada M
    Anticancer Res; 2019 Mar; 39(3):1433-1440. PubMed ID: 30842179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUV
    Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
    World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The patterns and risk factors for relapse in oesophageal squamous cell cancers that achieve pathological complete response to neoadjuvant chemoradiotherapy.
    Zhong J; Fang S; Chen R; Yuan J; Xie X; Lin T; Liu M; Liu Q; Fu J
    Eur J Cardiothorac Surg; 2024 Jun; 65(6):. PubMed ID: 38810125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of Inflammation-Based Factors in Patients with Esophageal Squamous Cell Carcinoma Achieving Pathological Complete Response After Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Kim JY; Yun JK; Kim YH; Park SI; Lee JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Kim SB; Cho KJ; Ryu JS; Kim JH; Kang J; Park SR; Kim HR
    Ann Surg Oncol; 2024 Oct; 31(10):6662-6672. PubMed ID: 38954089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictions of Pathological Features and Recurrence Based on FDG-PET Findings of Esophageal Squamous Cell Carcinoma after Trimodal Therapy.
    Hamai Y; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Furukawa T; Kurokawa T; Ohsawa M; Yoshikawa T; Okada M
    Ann Surg Oncol; 2020 Oct; 27(11):4422-4430. PubMed ID: 32405978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
    World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
    Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
    Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
    Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
    Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemoradiotherapy plus pembrolizumab for locally advanced esophageal squamous cell carcinoma with high risk of recurrence following neoadjuvant chemoradiotherapy: a single-arm phase II study.
    Guo JC; Huang TC; Kuo HY; Lin CC; Hsu FM; Cheng JC; Huang YL; Hsieh MS; Huang PM; Lee JM; Wu SL; Hsu CH
    Cancer Immunol Immunother; 2024 Sep; 73(11):230. PubMed ID: 39249605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
    Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
    Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
    Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
    BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
    Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
    BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinicopathological parameters predicting recurrence of pT1N0 esophageal squamous cell carcinoma.
    Xue LY; Qin XM; Liu Y; Liang J; Lin H; Xue XM; Zou SM; Zhang MY; Zhang BH; Hui ZG; Zhao ZT; Ren LQ; Zhang YM; Liu XY; Yuan YL; Ying JM; Gao SG; Song YM; Wang GQ; Dawsey SM; Lu N
    World J Gastroenterol; 2018 Dec; 24(45):5154-5166. PubMed ID: 30568392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma.
    Lu H; Liu JF; Rong Y; Liu XB; Wang Y
    J Gastrointest Surg; 2024 Jun; 28(6):867-869. PubMed ID: 38570232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of nodal status and lymphovascular invasion in patients undergoing neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Miyata H; Sugimura K; Kanemura T; Takeoka T; Sugase T; Yasui M; Nishimura J; Wada H; Akita H; Yamamoto M; Hara H; Shinno N; Omori T; Yano M
    Dis Esophagus; 2024 Aug; 37(9):. PubMed ID: 38693752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.